|
|||||||
|---|---|---|---|---|---|---|---|
|
|||||||
![]() |
Translational Science | Prope Tolerance and Depletional Therapy Allan D. Kirk, MD, PhD, FACS, Emory University B-cells and Alloantibodies Milagros D. Samaniego, MD, FACP, FASN, University of Michigan |
|||||
![]() |
Kidney Transplantation | Expanded Criteria Donors-Current Outcomes, Future Directions Akinlolu O. Ojo, MD, PhD, University of Michigan The Failed Transplant: Outcomes and Risks John Gill, MD, MS, The University of British Columbia |
![]() |
||||
![]() |
Liver Transplantation |
Clinical Outcomes of Liver Transplant for Hepatocellular Carcinoma |
![]() |
||||
![]() |
Cardiothoracic Transplantation | Pathophysiology and Treatment of BronchiolitIs Obliterans Scott M. Palmer, MD, MHS, FCCP, Duke University Diagnosis and Treatment of Antibody Mediated Rejection Jon A. Kobashigawa, MD, UCLA |
![]() |
||||
![]() |
Infectious Disease | HIV and Transplantation Shirish Huprikar, MD, Mount Sinai Medical Center Prevention and Treatment of BK Polyoma Nephropathy Daniel C. Brennan, MD, FACP, Washington University |
![]() |
||||